Which psoriasis cream causes less skin discoloration? new study aims to find out
NCT ID NCT05981118
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This study compares two standard psoriasis creams—a steroid and a newer drug called tapinarof—to see which one causes less skin color change after treatment. Forty adults with darker skin types will use one cream daily on their legs for up to 12 weeks. Researchers will track pigmentation changes, redness, and dryness to help doctors choose the best option for reducing lasting marks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Betamethasone dipropionate 0.05% cream and tapinarof 1% cream
- What this could lead to
- If successful, this study could help doctors choose a psoriasis treatment that leaves less lasting skin discoloration, especially for people with darker skin tones.
- What could go wrong
- This is a small, early-phase study with only 40 participants, so results may not apply to everyone. It compares two existing treatments, so no new drug is being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ICD10 CODE L40.9 FOR PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wake Forest University Health Sciences Department of Dermatology
Winston-Salem, North Carolina, 27157, United States